Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antipsychotic agents AND atypical antipsychotic AND schizophrenia AND veterans:

Search results

Items: 1 to 20 of 92

1.

Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.

Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.

Clin Ther. 2017 Jul;39(7):1380-1395.e4. doi: 10.1016/j.clinthera.2017.05.356. Epub 2017 Jun 20.

2.

An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.

Glynn SM, Marder SR, Noordsy DL, O'Keefe C, Becker DR, Drake RE, Sugar CA.

Psychiatr Serv. 2017 Mar 1;68(3):271-277. doi: 10.1176/appi.ps.201500171. Epub 2016 Nov 1.

PMID:
27799019
3.

Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.

Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

J Clin Psychiatry. 2016 Oct;77(10):e1332-e1341. doi: 10.4088/JCP.16m10745.

4.

Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study.

Chou PH, Chu CS, Lin CH, Cheng C, Chen YH, Lan TH, Huang MW.

Schizophr Res. 2016 Jul;174(1-3):137-143. doi: 10.1016/j.schres.2016.03.027. Epub 2016 Apr 6.

PMID:
27061658
5.
6.

Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.

Baser O, Xie L, Pesa J, Durkin M.

J Med Econ. 2015 May;18(5):357-65. doi: 10.3111/13696998.2014.1001514. Epub 2015 Jan 19.

PMID:
25525771
7.

Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

Liou YJ, Tsai SJ, Wang YC, Bai YM, Hong CJ.

J Clin Psychopharmacol. 2013 Jun;33(3):313-8. doi: 10.1097/JCP.0b013e31828bf288.

PMID:
23609384
8.

Use of second-generation antipsychotic agents for sleep and sedation: a provider survey.

Hermes ED, Sernyak M, Rosenheck R.

Sleep. 2013 Apr 1;36(4):597-600. doi: 10.5665/sleep.2554.

9.

TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.

Huang HH, Wang YC, Wu CL, Hong CJ, Bai YM, Tsai SJ, Liou YJ.

Neurosci Lett. 2011 Oct 31;504(3):277-80. doi: 10.1016/j.neulet.2011.09.046. Epub 2011 Sep 28.

PMID:
21967963
10.

Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson's disease.

Lan CC, Su TP, Chen YS, Bai YM.

Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):411.e3-5. doi: 10.1016/j.genhosppsych.2011.02.006. Epub 2011 Apr 1.

PMID:
21762841
11.

Diabetes prevalence estimates in schizophrenia and risk factor assessment.

Argo T, Carnahan R, Barnett M, Holman TL, Perry PJ.

Ann Clin Psychiatry. 2011 May;23(2):117-24.

PMID:
21547272
12.

Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.

Hong CJ, Chen TT, Bai YM, Liou YJ, Tsai SJ.

World J Biol Psychiatry. 2012 Jan;13(1):22-9. doi: 10.3109/15622975.2010.551543. Epub 2011 Mar 4.

PMID:
21375366
13.

Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.

Bai YM, Chen TT, Liou YJ, Hong CJ, Tsai SJ.

Schizophr Res. 2011 Feb;125(2-3):179-86. doi: 10.1016/j.schres.2010.11.030. Epub 2010 Dec 23.

PMID:
21185157
14.

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

Liou YJ, Bai YM, Lin E, Chen JY, Chen TT, Hong CJ, Tsai SJ.

Pharmacogenomics J. 2012 Feb;12(1):54-61. doi: 10.1038/tpj.2010.74. Epub 2010 Sep 28.

PMID:
20877301
15.

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.

Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ.

Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.

PMID:
20375926
16.

Management of schizophrenia with obsessive-compulsive features.

Hwang MY, Kim SW, Yum SY, Opler LA.

Psychiatr Clin North Am. 2009 Dec;32(4):835-51. doi: 10.1016/j.psc.2009.08.002. Erratum in: Psychiatr Clin North Am. 2010 Mar;33(1):xvii.

PMID:
19944887
17.

Management of schizophrenia with medical disorders: cardiovascular, pulmonary, and gastrointestinal.

Short DD, Hawley JM, McCarthy MF.

Psychiatr Clin North Am. 2009 Dec;32(4):759-73. doi: 10.1016/j.psc.2009.09.005. Review.

PMID:
19944882
18.

Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?

Housel AK, Waterbury N, Argo TR.

Issues Ment Health Nurs. 2009 Dec;30(12):803-5. doi: 10.3109/01612840903276712. Review. No abstract available.

PMID:
19916816
19.

American psychiatric association.

Alexander W.

P T. 2008 Jun;33(6):364-7.

20.

Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.

Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, Wang YC, Su TP, Chou P, Chen JY.

Schizophr Res. 2009 Jun;111(1-3):1-8. doi: 10.1016/j.schres.2009.03.014. Epub 2009 May 5.

PMID:
19409756

Supplemental Content

Loading ...
Support Center